|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. It operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers, including Alfaxan. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
- Michael Mccallister NEC (68)
- Kristin Peck CEO (49)
- Wetteny Joseph CFO (49)
- Roxanne Lagano CHO (56)
- Wafaa Mamilli EVP (53)
- Heidi Chen EVP (54)
- Timothy Bettington EVP (47)
- Robert Kelly EVP (49)
- J. Michael McFarland EVP (62)
- Abhay Nayak EVP (33)
- Robert Polzer EVP
- Sherry Pudloski EVP (53)
- Roman Trawicki EVP (57)
- Paul Bisaro IND (60)
- Frank D'amelio IND (63)
- Sanjay Khosla IND (69)
- Antoinette Leatherberry IND (59)
- Gregory Norden IND (63)
- Louise Parent IND (70)
- Willie Reed IND (66)
- Linda Rhodes IND (71)
- Robert Scully IND (71)
Latest News for ZTS
Upcoming Events for ZTS
Q4 2022 Zoetis Inc Earnings Release
Q1 2023 Zoetis Inc Earnings Release
Zoetis Inc Annual Shareholders Meeting
As of Today at 18:25 UTC, shares in Zoetis are trading at $157.42. This share price information is delayed by 15 minutes.
Shares in Zoetis last closed at $157.42 and the price had moved by -29.47% over the past 365 days. In terms of relative price strength the Zoetis share price has underperformed the S&P500 Index by -21.38% over the past year.
The overall consensus recommendation for Zoetis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Zoetis dividend yield is 0.78% based on the trailing twelve month period.
Last year, Zoetis paid a total dividend of $1.23, and it currently has a trailing dividend yield of 0.78%. We do not have any data on when Zoetis is to next pay dividends.
We do not have data on when Zoetis is to next pay dividends. The historic dividend yield on Zoetis shares is currently 0.78%.
To buy shares in Zoetis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $157.42, shares in Zoetis had a market capitalisation of $73.37bn.
Here are the trading details for Zoetis:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ZTS
Based on an overall assessment of its quality, value and momentum Zoetis is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zoetis is $213.45. That is 35.59% above the last closing price of $157.42.
Analysts covering Zoetis currently have a consensus Earnings Per Share (EPS) forecast of $4.88 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zoetis. Over the past six months, its share price has underperformed the S&P500 Index by -5.72%.
As of the last closing price of $157.42, shares in Zoetis were trading -6.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zoetis PE ratio based on its reported earnings over the past 12 months is 29.38. The shares last closed at $157.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zoetis' management team is headed by:
- Michael Mccallister - NEC
- Kristin Peck - CEO
- Wetteny Joseph - CFO
- Roxanne Lagano - CHO
- Wafaa Mamilli - EVP
- Heidi Chen - EVP
- Timothy Bettington - EVP
- Robert Kelly - EVP
- J. Michael McFarland - EVP
- Abhay Nayak - EVP
- Robert Polzer - EVP
- Sherry Pudloski - EVP
- Roman Trawicki - EVP
- Paul Bisaro - IND
- Frank D'amelio - IND
- Sanjay Khosla - IND
- Antoinette Leatherberry - IND
- Gregory Norden - IND
- Louise Parent - IND
- Willie Reed - IND
- Linda Rhodes - IND
- Robert Scully - IND